S2e-Leitlinie: Therapie akuter und chronischer immunvermittelter Neuropathien und Neuritiden

Sommer, Claudia

doi:10.1007/s42451-018-0022-6

Cited by 17 publications

(6 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While some costs might be of minor importance, the omission of costs of outpatient medical care, medication, devices and remedies for sequelae leads to an underestimation of the real costs: IBD and IBS patients mainly sought outpatient rather than inpatient medical care according to the claims data. GBS patients often need devices and physiotherapy supporting mobility and respiration [ 61 , 64 ] and severe GBS, REA and IBD cases require a costly immunomodulatory treatment [ 44 , 65 , 66 ].…”

Section: Discussionmentioning

confidence: 99%

Health care utilizations and costs of Campylobacter enteritis in Germany: A claims data analysis

et al. 2023

View full text Add to dashboard Cite

Objective The number of reported cases of Campylobacter enteritis (CE) remains on a high level in many parts of the world. The aim of this study was to analyze the health care utilizations and direct and indirect costs of CE and sequelae of patients insured by a large health insurance with 26 million members in Germany. Methods Claims data of insurants with at least one CE diagnosis in 2017 (n = 13,150) were provided, of which 9,945 were included in the analysis of health care utilizations and costs. If medical services were not diagnosis-linked, CE-associated costs were estimated in comparison to up to three healthy controls per CE patient. Indirect costs were calculated by multiplying the work incapacities by the average labor costs. Total costs of CE in Germany were extrapolated by including all officially reported CE cases in 2017 using Monte Carlo simulations. Results Insurants showed a lower rate of 56 CE diagnoses per 100,000 than German surveillance data for 2017, but with a similar age, gender and regional distribution. Of those CE cases, 6.3% developed post-infectious reactive arthritis, Guillain-Barré syndrome (GBS), inflammatory bowel disease (IBD) and/or irritable bowel syndrome (IBS). Health care utilizations differed depending on CE severity, age and gender. Average CE-specific costs per patient receiving outpatient care were € 524 (95% CI 495–560) over a 12-month period, whereas costs per hospitalized CE case amounted to € 2,830 (2,769–2,905). The analyzed partial costs of sequelae ranged between € 221 (IBS) and € 22,721 (GBS) per patient per 12 months. Total costs of CE and sequelae extrapolated to Germany 2017 ranged between € 74.25 and € 95.19 million, of which 10–30% were due to sequelae. Conclusion CE is associated with a substantial economic burden in Germany, also due to care-intensive long-lasting sequelae. However, uncertainties remain as to the causal relationship of IBD and IBS after CE.

show abstract

Section: Discussionmentioning

confidence: 99%

Health care utilizations and costs of Campylobacter enteritis in Germany: A claims data analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Kommt es unter den Therapien der 1. Wahl zu keinem ausreichenden Ansprechen, können Off-Label-Immunsuppressiva wie Cyclophosphamid, Ciclosporin A oder Rituximab eingesetzt werden [25]. [26].…”

Section: Chronische Inflammatorische Demyelinisierende Polyneuropathi...unclassified

Polyneuropathien im Alter

Held,

Üçeyler

2024

Klinische Neurophysiologie

View full text Add to dashboard Cite

Polyneuropathien (PNP) zählen zu den häufigsten neurologischen Erkrankungen des höheren Lebensalters. Durch Beeinträchtigung der Mobilität, Erhöhung des Sturzrisikos und neuropathische Schmerzen können sie die Lebensqualität der Patienten deutlich einschränken. Aufgrund der Vielzahl an möglichen Ursachen und weil häufig mehrere potenzielle Auslöser vorliegen, ist die Diagnostik gerade in höherem Lebensalter schwierig und erfordert ein systematisches Vorgehen.

show abstract

“…Kommt es unter den Therapien der 1. Wahl zu keinem ausreichenden Ansprechen, können Off-Label-Immunsuppressiva wie Cyclophosphamid, Ciclosporin A oder Rituximab eingesetzt werden [25].…”

Section: Chronische Inflammatorische Demyelinisierende Polyneuropathiunclassified

“…Als klinische Besonderheit findet sich hier zusätzlich zu der oben beschriebenen Symptomatik oft ein Tremor. Der Nachweis von Anti-MAG hat aber auch therapeutische Bedeutung, da diese Patienten ähnlich wie bei den seltenen axonalen Varianten schlechter auf die übliche immunmodulierende, CIDP-angelehnte Therapie ansprechen [25]. Bei Nachweis einer hämatoonkologischen Grunderkrankung steht deren Therapie im Vordergrund.…”

Section: Polyneuropathie Bei Monoklonalen Gammopathienunclassified

See 1 more Smart Citation